Hernix is a kinase inhibitor indicated for:
- Treatment of adult patients with early stage HER2 overexpressed breast cancer.
- Hernix can reduce risk of recurrence following Tastuzumab based therapy.
- Improve disease free survival
- Significant treatment benefit at 5 years.
It is an oral tablet production available in the strength of 40 mg.
This product is only for export.